NVS vs OMER: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: NVS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVS and OMER share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVS and OMER exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025.

Full NVS guide

Omeros Corporation develops drugs that target the complement system, the part of innate immunity that turns destructive in certain rare diseases. Its lead product, YARTEMLEA (narsoplimab-wuug), is a MASP-2 antibody approved by the FDA in December 2025 for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children two and older, a condition with high mortality and, until that approval, no approved treatment. Omeros also earns a royalty tail on OMIDRIA, the ophthalmic surgical drug it sold to Rayner in 2021, and in December 2025 it closed a deal handing global rights to its MASP-3 inhibitor zaltenibart (OMS906) to Novo Nordisk for $240 million in cash up front and up to $2.1 billion in total potential payments plus royalties. What remains in house is earlier stage: OMS1029, a long-acting MASP-2 antibody designed for quarterly dosing, and OMS527, a PDE7 inhibitor funded by NIDA for cocaine use disorder.

Full OMER guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.
• OMER drivers: The YARTEMLEA launch curve; A repaired balance sheet, not a raised one.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. For OMER, concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NVS if you believe its drivers more; OMER if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVS and OMER guides.

NVS. Figures are approximate and qualitative, tied to the asOf date; verify live numbers before acting. The near-term picture is a revenue and profit dip as blockbusters lose exclusivity, so the stock is best judged on whether the newer growth brands and pipeline can restore mid-single-digit growth over the medium term rather than on a single trailing quarter.

OMER. Screens that show Omeros at roughly 100 times sales are reading a trailing window that mostly predates the product: YARTEMLEA only began selling in January 2026. Against the second-quarter net revenue run rate of about $114 million annualized, the same market value is closer to nine times sales, which is an ordinary multiple for a rare-disease launch and a demanding one if the ramp stalls. Reported profitability is also flattered by one-time items, since first-half net income of about $69.3 million includes the Novo Nordisk transaction rather than recurring operations.

Headline figures (approximate, Jul 2026): NVS shows revenue (ttm) Approximately $50 billion in annual net sales; Q1 2026 net sales were about $13.1 billion, down roughly 5% at constant currency on generic erosion, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix growing well above 50% at constant currency, offsetting Entresto's decline, margins/profitability High core operating margin, around 40% in 2025; 2026 guidance is for a low single-digit decline in core operating income on generic and R&D pressure, dividend Pays an annual dividend with a long record of increases; yield has recently been roughly 2%, subject to currency and Swiss withholding tax for ADR holders; OMER shows net product revenue (q2 2026) ~$28.5M (~$32.2M gross), net product revenue (h1 2026) ~$38.4M, versus $0 a year earlier, net income (q2 2026) ~$13.2M, or ~$0.18 per share, cash and short-term investments ~$132M as of June 30, 2026.

NVS and OMER are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVS and OMER exposure against your real portfolio. It is not an investment adviser.